Tag archive for ‘Ebola treatments. Brincidofovir use against Ebola’
Chimerix: A Review of Recent Analyst Day Presentations with a Focus on Adenovirus and Ebola (CMRX, $31.31, Neutral)
The fundamental outlook for Chimerix is very attractive in my opinion. My model suggests that sales of its lead drug brincidofovir could reach $800 million in 2021 based only on use in allogeneic hematopoietic stem cell and other severely immunocompromised patients. It could have significant uses beyond this. Topline data on the phase 3 SUPPRESS […]